Evidence map›Paper›PMID 34131623›Full record

ArticleRheumatology advances in practice2021

Rheumatoid arthritis patients with predominantly tender joints rarely achieve clinical remission despite being in ultrasound remission.

Hilde Berner Hammer, Inger Marie Jensen Hansen, Pentti Järvinen, Marjatta Leirisalo-Repo, Michael Ziegelasch, Birte Agular, Lene Terslev

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Rheumatology advances in practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02046616 (Tocilizumab SC in Patients With Active Rheumatoid Arthritis and Inadequate Response to DMARDs. A Single-Arm, Open-Label Study to Evaluate Safety, Tolerability and Efficacy. In a Subgroup of Patients Inflammation Will Be Measured by Ultrasound.), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02046616 phase3completednot on this map

Tocilizumab SC in Patients With Active Rheumatoid Arthritis and Inadequate Response to DMARDs. A Single-Arm, Open-Label Study to Evaluate Safety, Tolerability and Efficacy. In a Subgroup of Patients Inflammation Will Be Measured by Ultrasound.

TypeinterventionalSponsorHoffmann-La RocheRan2014 to 2016Enrolled133ConditionsRheumatoid ArthritisArmsTocilizumab, Methotrexate, Non-Biologic DMARDs
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. EXPLORing Arthritis with Total-body Positron Emission Tomography.Seminars in musculoskeletal radiology · 2023
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 4 countries.

Hilde Berner HammerDepartment of Rheumatology, Diakonhjemmet Hospital.ORCID https://orcid.org/0000-0001-7317-8991
Inger Marie Jensen HansenDepartment of Rheumatology, Svendborg Sygehus, Svendborg, Denmark.
Pentti JärvinenDepartment of Rheumatology, Kiljava Medical Research, Hyvinkää.
Marjatta Leirisalo-RepoDepartment of Rheumatology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0002-1568-9045
Michael ZiegelaschDepartment of Rheumatology, University Hospital, Linköping, Sweden.
Birte AgularRoche, Hvidovre, Denmark.
Lene TerslevCentre for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Copenhagen, Denmark.ORCID https://orcid.org/0000-0001-8193-9471
Glostrup Hospital · DKLinköping University Hospital · SERoche (Denmark) · DKSvendborg Sygehus · DKUniversity of Helsinki · FIUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesGiven that subjective variables might reduce remission by composite DAS (CDAS), the main objectives were to explore whether RA patients with mainly tender

methodsIn a Nordic multicentre study, RA patients initiating tocilizumab were assessed by PROMs, clinical, laboratory and US assessments (36 joints and 4 tendons) at baseline, 4, 12 and 24 weeks. Remission was defined according to clinical disease activity index (CDAI)/Boolean or no Doppler activity present. Tender-swollen joint differences (TSJDs) were calculated. Statistics exploring changes over time/differences between groups included Wilcoxon, Mann-Whitney, Kruskal-Wallis and Spearman tests.

resultsOne hundred and ten patients were included [mean (s.d.) age 55.6 (12.1) years, RA duration 8.7 (9.5) years]. All PROMs, clinical, laboratory and US scores decreased during follow-up (

conclusionPatients with more tender than swollen joints scored higher on subjective assessments but had less US synovitis. They seldom achieved CDAS remission despite many being in Doppler remission. If patients with predominantly tender joints do not reach CDAS remission, objective assessments of inflammation should be performed.

trial registrationClinicalTrials.gov, https://clinicaltrials.gov/, NCT02046616.

Indexed as

biological treatmentpatient-reported outcomesrheumatoid arthritisultrasound

Identifiers

PMID34131623
PMCPMC8195913
OpenAlexW3161307733

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.